Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Forecast Insight: Antihypertensives Key patent expiries prevent market growth

Forecast Insight: Antihypertensives Key patent expiries prevent market growth

Datamonitor expects the antihypertensives market to reach $37 billion, across the seven major markets, by 2017. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.

Description of the competitive landscape in antihypertensives across seven major markets with market definition and overview.

Definition of the unmet needs in the antihypertensives market.

Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.

Analysis of major events and brand dynamics affecting the hypertension market.

The growth rate of the antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favour of developing more efficacious combination therapies.

Cozaar's and Diovan's patent expiries in the US have the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.

Novartis is set to strengthen its position in the antihypertensives arena; Tekturna is expected to achieve moderate sales and together with Exforge form a potential for market expansion. This however will be set back by the premature expiry of Pfizer's Norvasc patent.

Quantify the future size of the antihypertensives market and identify opportunities for new products.

Learn how recent changes related to product expiries will shape the antihypertensives market.

Understand the barriers to uptake for novel antihypertensive agents, and the need for paradigm shift in clinical trial design.

Publication: 39630
Library Code: DMHC2436
Type: Report
Format: PDF & DataPack
Pages: 96

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions